Donald W. DeGolyer, a director at Emergent BioSolutions Inc., sold 17,800 shares of the company on October 7, 2026. This sale is significant as it was executed to satisfy tax obligations related to the vesting of restricted stock units (RSUs) on October 2, 2026.
The transaction was conducted under a Rule 10b5-1 trading plan established on August 11, 2025. Following this transaction, DeGolyer retains ownership of 111,921 shares of Emergent BioSolutions.
Background
Emergent BioSolutions Inc. is a company focused on pharmaceutical preparations, particularly in the life sciences sector. The company is incorporated in Delaware and has its business headquarters in Gaithersburg, Maryland. Emergent BioSolutions trades under the ticker symbol EBS.
What the Filing Says
"Shares were sold pursuant to a Rule 10b5-1 trading plan... for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2026."
Impact
This sale may influence shareholders and potential investors who monitor insider trading activities as a measure of company confidence and financial health. DeGolyer's actions may also reflect broader trends in the pharmaceutical industry, particularly regarding stock management and compensation strategies.
What's Next
The filing does not say what happens next.
Transaction Details
Donald W. DeGolyer sold the 17,800 shares at a weighted average price of $7.09. The shares were sold in multiple transactions, with prices ranging from $6.88 to $7.24. This detailed pricing information indicates that the sale was executed across a range of market conditions, which is common in such transactions.
Ownership Structure
After the sale, DeGolyer continues to hold a significant number of shares, totaling 111,921 shares of Emergent BioSolutions. This level of ownership suggests a continued commitment to the company, despite the recent sale aimed at fulfilling tax obligations.
Legal and Compliance Notes
The transaction was reported under Form 4, which is required for insiders to disclose their trades in company securities. This filing reflects compliance with SEC regulations, ensuring transparency in insider trading activities.
Additional Context
The filing does not provide information on DeGolyer's future intentions regarding his remaining shares, nor does it discuss any potential impact on the company's stock performance or investor sentiment beyond the immediate effects of this transaction.